voting rights

47 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Syensqo

BlackRock Crosses 3% Threshold in Syensqo, Signals Major Institutional Vote

BlackRock notifies Syensqo of 3.95% stake crossing Belgian disclosure threshold, signaling institutional confidence in specialty chemicals post-separation.
BLKDIVBSYNSYvoting rightsBlackRock
GlobeNewswire Inc.GlobeNewswire Inc.··Na

BlackRock Cuts Stake in Endeavour Mining to 13.03% Amid Portfolio Rebalancing

BlackRock reduced voting rights in Endeavour Mining from 13.85% to 13.03%, reflecting decreased direct holdings and derivative positions.
BLKDIVBvoting rightsBlackRock
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Orange Secures €1.3B Financing for Scorefit Acquisition

Orange secures €1.3 billion financing from CaixaBank and BNP Paribas to fund Scorefit acquisition, disclosing share capital details ahead of May 19 shareholders' meeting.
ORANYBNPZYCAIXYacquisitionvoting rights
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Orange Secures €1.3B Financing for Scorefit Acquisition Amid Share Capital Disclosure

Orange secures €1.3B financing from CaixaBank and BNP Paribas for Scorefit acquisition; discloses 2.66B shares outstanding as of April 30, 2026.
ORANYBNPZYCAIXYacquisitionvoting rights
BenzingaBenzinga··Badar Shaikh

Musk's Iron Grip: SpaceX IPO Filing Reveals CEO Can Only Fire Himself

SpaceX IPO filings reveal Elon Musk holds Class B shares with 10 voting rights each, making him effectively irremovable without his consent and limiting investor influence.
METAGOOGGOOGLvoting rightscorporate governance
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Worldline Executes 40-for-1 Reverse Stock Split to Streamline Capital Structure

Worldline implements 40-for-1 reverse stock split effective June 15, 2026, reducing shares to 56.57 million while maintaining total shareholder value.
WRDLYvoting rightsshare consolidation
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Lufthansa Files Shareholding Disclosure Under German Securities Law

Lufthansa files mandatory shareholding disclosure under German securities law, confirming independent control structure with no hidden shareholder linkages.
DLAKYvoting rightsshareholding
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Lufthansa Files Regulatory Disclosure on Shareholding Structure

Deutsche Lufthansa files mandatory shareholding disclosure under German securities law, confirming governance independence and regulatory compliance across European markets.
DLAKYvoting rightsregulatory notification
GlobeNewswire Inc.GlobeNewswire Inc.··Syensqo

BlackRock Crosses 3% Threshold in Syensqo, Signaling Major Investor Interest

BlackRock crosses 3% voting threshold in Syensqo with 3.95% total stake, triggering Belgian disclosure requirements and signaling major institutional investor confidence.
BLKDIVBSYNSYvoting rightsshareholding
The Motley FoolThe Motley Fool··Cory Renauer

Revolve Co-CEO Sells $414K in Shares as Company Posts Strong Earnings Growth

Revolve Group Co-CEO Michael Mente sold 16,000 shares for $414,000, retaining majority control. Company reports robust Q4 results with 10% sales growth and 58% net income surge.
RVLVe-commercevoting rights
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Barclays Exits Major Stake in Diversified Energy, Voting Rights Drop Below Threshold

Barclays PLC exits major 5.2% stake in Diversified Energy Company UK, with voting rights dropping below reportable threshold following April 9 threshold crossing.
DECBCSvoting rightsthreshold crossing
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Citigroup Cuts Solvay Stake Below 3% Threshold via Financial Instruments

Citigroup's shareholding in Solvay dropped below 3% on April 10, 2026, through derivative positions, triggering mandatory Belgian transparency disclosure.
CCpNCpRvoting rightstransparency notification
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Citigroup Exits Solvay Stake Below 3% Threshold via Financial Instrument Disposal

Citigroup divested financial instruments tied to Solvay shares, triggering disclosure as its voting rights fell below the 3% regulatory threshold on April 10, 2026.
CCpNCpRvoting rightsshareholding
GlobeNewswire Inc.GlobeNewswire Inc.··Solar A/S

UBS Reduces Solar A/S Stake to 3.18% in Major Shareholder Shift

UBS Group AG sold shares in Solar A/S, reducing stake to 25.5M Class B shares (3.18% voting rights) as of April 7, 2026.
UBSvoting rightsshare sale
GlobeNewswire Inc.GlobeNewswire Inc.··Dassault Systèmes

Dassault Systèmes Reports Share Count, Voting Rights in Regulatory Filing

Dassault Systèmes files regulatory disclosure showing 1.34 billion shares and 2.01 billion voting rights as of March 31, 2026, in standard French market compliance.
DASTYregulatory compliancevoting rights
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Dassault Systèmes Discloses Share Capital Composition; 1.34B Shares Outstanding

Dassault Systèmes reports 1.34 billion shares outstanding and 2.01 billion voting rights as of March 31, 2026, in compliance with French regulatory requirements.
DASTYvoting rightsMarch 31, 2026
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Dior Discloses Capital Structure as Shareholder Meeting Approaches

Christian Dior reports 180.5M shares and 356.8M voting rights as of March 31, 2026, ahead of April shareholder meeting.
CHDRYvoting rightsannual report
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Ontex Schedules May 2026 Shareholder Meeting as Major Investor Stakes Drop Below 3%

Ontex schedules May 2026 shareholder meeting as major investor Niessen/Mont Cervin stake falls below 3% threshold.
ONXYYvoting rightscorporate governance
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Ontex Charts Future Course as Leadership Stake Dips Below 3%

Ontex scheduled May 2026 shareholder meeting; major stakeholder's voting rights fell below 3% threshold in March shift.
ONXYYvoting rightsAnnual General Meeting
GlobeNewswire Inc.GlobeNewswire Inc.··Na

DBV Technologies Reports 296M Shares Outstanding as Clinical Pipeline Advances

DBV Technologies reports 296M shares outstanding and 296M voting rights as of March 31, 2026, with updates on VIASKIN® Peanut Patch clinical programs.
DBVTfinancial resultsclinical development